Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
December 18, 2025
Financial Statements and Highlights | Takeda Investor Relations
Financial Highlights
Loading feed metadata...
Sign up for our investors newsletter
Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet
Sign up